Hbk Sorce Advisory LLC Crispr Therapeutics Ag Transaction History

Hbk Sorce Advisory LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$70.09 - $111.29 $130,507 - $207,221	-1,862 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$110.2 - $156.64 $4,959 - $7,048	45 Added 2.48%	1,862 $208,000
Q2 2021 Aug 12, 2021	BUY	$100.84 - $161.89 $14,117 - $22,664	140 Added 8.35%	1,817 $294,000
Q1 2021 May 14, 2021	BUY	$110.72 - $210.04 $185,677 - $352,237	1,677 New	1,677 $204,000
Q2 2019 Aug 14, 2019	SELL	$35.45 - $48.2 $231,488 - $314,746	-6,530 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$28.02 - $40.87 $182,970 - $266,881	6,530 New	6,530 $233,000
Q4 2018 Feb 14, 2019	SELL	$22.73 - $42.34 $149,313 - $278,131	-6,569 Closed	0 $0
Q3 2018 Nov 15, 2018	SELL	$44.35 - $65.71 $33,706 - $49,939	-760 Reduced 10.37%	6,569 $291,000
Q2 2018 Aug 10, 2018	BUY	$42.62 - $73.59 $103,055 - $177,940	2,418 Added 49.24%	7,329 $0
Q1 2018 May 15, 2018	BUY	$23.52 - $58.17 $115,506 - $285,672	4,911 New	4,911 $224,000

488

64.1M

1.64M

1.93M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.2B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Hbk Sorce Advisory LLC, based on Form 13F filings with the SEC.

Stay updated on Hbk Sorce Advisory LLC with notifications on news.